Anu George, MD
Internal Medicine · Falls Church, VANPI 1558391136
Payments from drug & device makers
Across 519 payments — averaging $1053.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$209K
- Boehringer Ingelheim$205K
- AbbVie$81K
- Boehringer Ingelheim Pharma GmbH & Co.kg$18K
- Boehringer Ingelheim International GmbH$15K
- Novo Nordisk AS$6K
- plus $11K from 30 others
Across 10 payments — averaging $105.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Travel & lodging$1,97926%
- Food & beverage$5,62674%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 93 | $209,365 |
| Boehringer Ingelheim | 32 | $205,125 |
| AbbVie(2 entities) | 59 | $80,687 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $18,362 |
| Boehringer Ingelheim International GmbH | 116 | $15,493 |
| Novo Nordisk AS | 5 | $6,400 |
| Sanofi US Services Inc. | 2 | $4,947 |
| Amarin Pharma, Inc. | 3 | $2,200 |
| Lilly USA, LLC | 49 | $892 |
| AstraZeneca | 36 | $825 |
| Novo Nordisk | 30 | $569 |
| Gilead | 8 | $374 |
| Merck | 18 | $233 |
| Astellas Pharma US Inc | 7 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $134 |
| Pfizer | 6 | $109 |
| Abbott | 5 | $104 |
| Amgen | 5 | $81 |
| Kowa Pharmaceuticals America, Inc. | 4 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Genentech USA, Inc. | 3 | $42 |
| Hikma Pharmaceuticals USA | 3 | $38 |
| Hologic Sales And Service, LLC | 2 | $37 |
| Lumenis, Inc | 1 | $32 |
| Lundbeck LLC | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Corcept Therapeutics | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Eyevance Pharmaceuticals LLC | 2 | $24 |
| Exact Sciences | 1 | $18 |
| IBSA Pharma Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$546,616 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $110,727 |
| JardianceEmpagliflozin | 41 | $60,640 |
| MounjaroTirzepatide | 32 | $47,902 |
| EliquisApixaban | 14 | $22,918 |
| LinzessLinaclotide | 16 | $19,144 |
| FarxigaDapagliflozin Propanediol | 12 | $12,962 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $12,431 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,317 |
| Atorvastatin Calcium | 286 | $2,244 |
| SynthroidLevothyroxine Sodium | 12 | $2,147 |
| Rosuvastatin Calcium | 135 | $2,127 |
| Levothyroxine Sodium | 126 | $1,639 |
| Metoprolol Succinate | 88 | $1,626 |
| Losartan Potassium | 139 | $1,504 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $1,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $569 | $110,72779 claims |
| Boehringer IngelheimJardiance | $205,125 | $60,64041 claims |
| Lilly USA, LLCMounjaro | $892 | $47,90232 claims |
| PfizerEliquis | $109 | $22,91814 claims |
| AbbVieLinzess, Synthroid | $80,687 | $21,29128 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $209,365 | $17,74831 claims |
| AstraZenecaFarxiga | $825 | $12,96212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Falls Church
- Amit MahajanFalls Church$1.3M
- Kevin DonohueFalls Church$655K
- Sheinei AlanFalls Church$352K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.